The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
CellPoint
Oegstgeest, Netherlands
A
1-10 Employees
2018
Key takeaway
Engineered T cells using chimeric antigen receptors (CAR-Ts) have revolutionized cancer treatment by effectively eradicating tumors and offering long-lasting remissions. However, the traditional production process for first-generation CAR-Ts is complex and resource-intensive.
Reference
Service
Services – CellPoint B.V.
CAR-T therapies at the point-of-care
T Cell Nouveau
Tokyo, Japan
A
1-10 Employees
2021
Key takeaway
T Cell Nouveau Inc. is advancing CAR-T cell therapy through its innovative Hybrid CAR T-cell approach, which they believe is a significant advancement in the fight against solid tumors, surpassing traditional CAR and TCR-T cell therapies. Their commitment to research and development in cancer immunotherapeutics positions them at the forefront of this transformative technology.
Reference
Product
Technology | T Cell Nouveau Inc.
CAR-T細胞治療 自己由来CAR-T細胞治療
Carina Biotech
Adelaide, Australia
A
1-10 Employees
2016
Key takeaway
Carina Biotech is at the forefront of developing next-generation CAR-T cell therapies that harness the patient's immune system to combat cancer, offering a promising new treatment option.
Reference
Core business
Carina Biotech | Fighting Cancer with CAR-T Technologies | Australia
Carina Biotech are creating a future that defeats cancer. Empowering patients to fight cancer through next-generation CAR-T therapies. Find out more.
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Gracell Biotechnologies
Suzhou City, China
D
51-100 Employees
2017
Key takeaway
Gracell Biotechnologies is focused on developing innovative CAR-T cell therapies, utilizing a next-day manufacturing platform to produce younger and more active T cells, aiming to provide fast and durable responses for cancer and autoimmune disease patients.
Reference
Core business
Gracell | Pioneering Next Generation CAR-T Therapies
CARsgen Therapeutics
Shanghai, China
D
11-50 Employees
2014
Key takeaway
CARsgen is a biopharmaceutical company that has developed a promising CAR T-cell therapy, zevorcabtagene autoleucel (zevor-cel or CT053), aimed at treating relapsed/refractory multiple myeloma. With a strong manufacturing presence in both China and the U.S., CARsgen is well-positioned to advance its innovative cell therapies for cancer patients.
Reference
Core business
Company Overview | CARsgen
Kite Pharma
Los Angeles, United States
B
51-100 Employees
2009
Key takeaway
Kite Pharma is dedicated to developing innovative cell therapies, including CAR-T cell therapy, which involves engineering a patient's own immune cells to specifically target and attack cancer. Their focus on research and development, bolstered by strategic partnerships, enhances their ability to transform cancer treatment and improve patient outcomes.
Reference
Core business
Transformational Cancer Treatment | Kite Pharma
Learn about Kite’s mission to change the way cancer is treated with cell therapy – the use of genetically modified immune cells programmed to target tumors.
TC BioPharm
Holytown, United Kingdom
A
11-50 Employees
2013
Key takeaway
TC BioPharm is focused on developing advanced allogeneic CAR-T cell therapy products aimed at treating cancer more effectively and affordably. Their mission emphasizes innovation in cell-based therapies to improve patient health and quality of life.
Reference
Core business
Home • TC BioPharm
TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer.
Atara Biotherapeutics
South San Francisco, United States
B
251-500 Employees
2012
Key takeaway
Atara Biotherapeutics is focused on developing off-the-shelf, allogeneic T-cell immunotherapies, positioning itself as a leader in the CAR-T cell therapy space. With a commitment to harnessing the immune system's power, the company is advancing innovative treatments for cancer and other diseases.
Reference
Core business
Allogeneic T-cell Immunotherapy Company - Atara Biotherapeutics
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.
Catamaran Bio
Cambridge, United States
B
11-50 Employees
2020
Key takeaway
The company, Catamaran Bio, is focused on developing innovative CAR-NK cell therapies that enhance the cancer-fighting potential of Natural Killer cells. Their TAILWIND® platform integrates advanced technologies to create transformative, off-the-shelf treatments for solid tumors and other cancers, aiming to significantly improve patient outcomes.
Reference
Core business
Home - Catamaran Bio
Catamaran harnesses the natural cancer-fighting properties of NK cells, the power of synthetic biology and innovative non-viral cell engineering to create novel CAR-NK cell therapies
Tessa Therapeutics
Singapore, Singapore
C
101-250 Employees
2001
Key takeaway
Tessa Therapeutics is focused on developing innovative cell therapies for cancer, including their unique allogeneic CD30-CAR EBVST platform, which targets a wide range of cancers. This approach represents a significant advancement in the field of CAR-T cell therapy.
Reference
Product
Technology | Tessa Therapeutics – Cancer Immunotherapy Treatments
A comprehensive approach to cancer immunotherapy. Successful cancer immunotherapy treatments mimic core aspects of the body’s anti-viral immune response.
Technologies which have been searched by others and may be interesting for you:
CAR-T Cell Therapy is an innovative treatment that modifies a patient's T cells to better recognize and attack cancer cells. This process involves collecting T cells from the patient’s blood and then genetically engineering them in a laboratory to express chimeric antigen receptors (CARs). These engineered cells are infused back into the patient, enabling them to target specific proteins on cancer cells. This therapy has shown remarkable success in treating certain types of blood cancers, such as acute lymphoblastic leukemia and large B-cell lymphoma. By harnessing the body’s immune system, CAR-T Cell Therapy offers a personalized approach to cancer treatment, providing hope for patients with otherwise limited options.
CAR-T cell therapy is a groundbreaking cancer treatment that utilizes a patient's own immune cells to target and destroy cancer cells. The process begins with the collection of T cells from the patient's blood. These T cells are then genetically modified in a laboratory to express a chimeric antigen receptor (CAR) that specifically recognizes cancer cells. Once the T cells are engineered, they are multiplied to create a substantial number of CAR-T cells. After this expansion phase, the modified cells are infused back into the patient. The CAR-T cells then seek out and bind to the cancer cells, triggering an immune response that leads to the destruction of those cells. This innovative therapy has shown promising results, particularly in treating certain types of blood cancers.
1. Targeted Treatment
CAR-T cell therapy offers a highly targeted approach to cancer treatment, utilizing genetically modified T cells to specifically recognize and attack cancer cells. This precision reduces damage to healthy cells, minimizing side effects compared to traditional therapies.
2. Long-lasting Remission
Patients often experience durable remissions, as the engineered T cells can persist in the body and continue to monitor for cancer recurrence. This potential for long-term effectiveness makes CAR-T cell therapy a promising option for relapsed or refractory cancers.
CAR-T Cell Therapy has shown promise in treating various types of cancers, particularly hematological malignancies. Specifically, it is effective for certain types of leukemia, such as acute lymphoblastic leukemia (ALL), and lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Additionally, CAR-T Cell Therapy is being explored for other cancers like multiple myeloma and some solid tumors, although its application in these areas is still under investigation. The innovative approach of modifying T cells to target cancer cells has significantly advanced treatment options for patients with these specific malignancies.
CAR-T Cell Therapy can lead to several potential side effects that patients should be aware of. One of the most common is cytokine release syndrome (CRS), which occurs when the activated T cells release a large amount of cytokines into the bloodstream. This can result in symptoms like fever, fatigue, nausea, and in severe cases, breathing difficulties and organ dysfunction. Another significant side effect is neurotoxicity, which may manifest as confusion, seizures, or difficulty speaking. Patients might also experience low blood cell counts, leading to increased risk of infections, anemia, or bleeding. Monitoring and managing these side effects is crucial for ensuring patient safety throughout the treatment process.
Some interesting numbers and facts about your company results for CAR-T Cell Therapy
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 6938 |
| Amount of suitable service providers | 5675 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2001 |
| Youngest suiting company | 2021 |
20%
40%
60%
80%
Some interesting questions that has been asked about the results you have just received for CAR-T Cell Therapy
What are related technologies to CAR-T Cell Therapy?
Based on our calculations related technologies to CAR-T Cell Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of CAR-T Cell Therapy?
Start-Ups who are working in CAR-T Cell Therapy are T Cell Nouveau, Catamaran Bio
Which industries are mostly working on CAR-T Cell Therapy?
The most represented industries which are working in CAR-T Cell Therapy are Biotechnology, Other, IT, Software and Services, Healthcare, Medical
How does ensun find these CAR-T Cell Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
